LPCN stock


Lipocine Inc (LPCN) Stock Is Now a “Show Me” Story

Odds of approval for LPCN’s Tlando come May 8th? H.

Lipocine Inc. (LPCN): FDA Panel Gives Thumbs Down to TLANDO, What’s Next?

While Lipocine investors run for the hills following negative advisory committee meeting, Canaccord’s Dewey Steadman still sees a light at the end of the tunnel.

Lipocine Inc (LPCN) Fails to Convince FDA Advisory Committee of TLANDO’s Merit; Shares Decline Over 50%

Lipocine Inc (NASDAQ:LPCN) failed to convince the Food and Drug Administration advisory committee that its phase 3 data testing TLANDO in hypogonadal male …

Bull Believes Lipocine Inc (LPCN) Oral Testosterone Candidate Eventually Approvable, But Not Betting on Today’s FDA Meeting

Canaccord’s Dewey Steadman says once LPCN’s Tlando gets the safety data it needs in hand to impress the FDA, a green light will flash.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts